长三角地区依托雄厚的产业基础、完善的配套设施和活跃的民营经济，以高端制造与科技创新为引领， 在高新技术产品上形成了集群优势。该地区以上海为龙头，苏浙皖各展所长，江海联运与港口群联 动，"研发—转化—制造"全链条协同，通过制度型开放与数字经济赋能，不断提升在价值链中的附加 值。这种发展路径有赖于强大的地区创新能力和内生增长动力、高效的域内要素配置及良好的营商环 境。 粤港澳大湾区则充分发挥了港澳区位优势和"一国两制"制度优势。其独特禀赋体现在高度国际化、市场 化以及作为联通国内国际循环的桥梁。该地区依托香港的国际金融、国际枢纽港和国际贸易中心地位， 在传统优势产业基础上，以机电产品和"新三样"为出口主力，实现了高效的跨境物流与规则衔接，加上 珠三角地区作为世界级制造业基地的实力，不断整合资源，巩固其全球供应链与贸易枢纽的地位，深度 融入国际经济合作。 今年以来，面对复杂的国际经贸环境，长三角、粤港澳大湾区、京津冀，这三大重要经济区域，凭借各 具特色的产业禀赋与区位特点取得了令人振奋的外贸成绩。作为国家经济发展的战略支点，三大区域通 过功能互补、协同联动，构建起"各美其美""美美与共"的发展格局，共同服务于国家整 ...

Core Insights - McKesson Corporation, based in Irving, Texas, is one of America's oldest businesses with a market capitalization of approximately $105.6 billion, focusing on pharmaceutical distribution, medical supply delivery, and technology solutions [1] Market Performance - Over the past 52 weeks, McKesson's stock has increased by 39.8% and by 51% year-to-date, significantly outperforming the S&P 500 Index, which gained 12.3% and 12.5% in the same periods [2] - The stock has also outperformed the S&P 500 Healthcare Sector SPDR, which saw a 7.5% increase over the past 52 weeks and a 10.9% rise year-to-date [3] Financial Results - For the second quarter of fiscal year 2026, McKesson reported a revenue increase of 10.1% year-over-year, reaching $103.2 billion, aligning with analyst expectations, driven by stronger prescription volumes and broader distribution of oncology and multispecialty products [4] - Earnings per share (EPS) surged 377% annually to $8.92, surpassing expectations, and the management has raised its adjusted EPS outlook for fiscal year 2026 to a range of $38.35 to $38.85 [5] Analyst Outlook - Analysts forecast a 17% EPS growth to $38.66 on a diluted basis for the fiscal year ending in March 2026, with McKesson exceeding analyst expectations for three consecutive quarters [6] - The consensus rating among 16 analysts covering McKesson is "Strong Buy," with 13 "Strong Buy" calls and three "Hold" recommendations [6] - Following the Q2 results, Baird analyst Eric Coldwell raised McKesson's price target to $927 from $873, maintaining an "Outperform" stance, indicating confidence in the company's momentum [7]

This story was originally published on Supply Chain Dive. To receive daily news and insights, subscribe to our free daily Supply Chain Dive newsletter. The United States secured new framework trade agreements last week that would lower one of its highest country-specific tariff rates while allowing certain duty exemptions for four nations in Central and South America. In a framework agreement with Switzerland and Liechtenstein, the U.S. said it would slash the current 39% tariff charged to imports of Swi ...

Lakewood, CO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- KRTL Holding Group Inc. (OTC: KRTL) (the “Company”) reported financial results for the three and nine months ended September 30, 2025, and announced the completion of a PCAOB audit of its consolidated financial statements for the years ended December 31, 2024, and 2023. Cesar Herrera, the Company’s Chief Executive Officer, said: “We are pleased to announce that we now have PCAOB-audited financial statements for our previous two fiscal years and that there were ...

Working with the Swiss. What we've done is we've identified the areas in the reasons why we have a big deficit with them in goods. And it really boils down to things like pharmaceuticals, gold, right.Trade in gold and a handful of other things. And so the Swiss, as part of their agreement, you know, they said we are going to have $200 billion in investment. The trade as in Trump's term, you know, starting with about $70 billion investment next year.And it will be in these areas, we expect that the Swiss wil ...

President Trump has announced frameworks for agreements on reciprocal t trade with El Salvador, Argentina, Ecuador, and Guatemala. Joining us right now on the latest on trade negotiations is United States Trade Representative, Ambassador Jameson Greer. And Ambassador, thank you for being here today.Uh the way it's being boiled down, at least in the headlines, and tell us if this is the right way of seeing this, is that there are going to be uh exemptions to these terri tariff barriers that are there for goo ...

Core Insights - Cardinal Health, Inc. has significantly outperformed the broader market in 2025 and over the past year, with stock prices increasing by 66.4% in 2025 and 73.9% over the past 52 weeks, compared to the S&P 500 Index's gains of 15.6% year-to-date and 17.5% over the past year [2][4] Company Performance - The company reported a robust Q1 performance on October 30, with a year-over-year revenue increase of 22.4% to $64 billion, surpassing expectations by 8.4% [4] - Adjusted EPS for the quarter surged 35.6% year-over-year to $2.55, exceeding consensus estimates by 15.4% [4] - For the full fiscal 2026, analysts project an adjusted EPS of $9.92, reflecting a 20.4% year-over-year increase [5] Analyst Ratings - Among 15 analysts covering Cardinal Health, the consensus rating is a "Strong Buy," consisting of 11 "Strong Buys" and four "Holds" [5] - Wells Fargo analyst Stephen Baxter maintained an "Overweight" rating on Cardinal Health and raised the price target from $185 to $221, indicating a potential upside from current levels [6]

Group 1 - Baxter International's stock experienced a significant decline of nearly 15% following a mixed third-quarter report that missed analyst profitability estimates [1] - Total sales for Baxter rose by 5% year over year to $2.84 billion, while net income not according to GAAP decreased by 14% to $355 million ($0.69 per share) [2] - The revenue figure fell short of the consensus analyst estimate of $2.88 billion, although the adjusted net profit exceeded the projection of $0.60 [3] Group 2 - Baxter's business segments showed varied performance, with Pharmaceuticals leading growth at 7% to $632 million, Healthcare Systems and Technologies increasing by 3% to $773 million, while Medical Products and Therapies declined by 1% to just under $1.33 billion [4] - The "other" category saw a significant increase, rising more than fivefold to $101 million [4] - Management's guidance for the full year anticipates sales growth of only 1% to 2% over the 2024 result, with adjusted net income forecasted at $2.35 to $2.40 per share, below the average analyst estimate of $2.44 [5]

Core Insights - Cardinal Health is investing significantly in modernizing and expanding its pharmaceutical logistics distribution network to enhance efficiency and customer responsiveness [1][2] Group 1: Major Projects - The newly opened Consumer Health Logistics Center in Groveport, Ohio, and a planned flagship pharmaceutical distribution center in Indianapolis are central to Cardinal Health's long-term strategy [2][3] - The Groveport facility is a cornerstone of the hub-and-spoke distribution model, while the Indianapolis center aims to meet expanding demand and set new operational standards [3] Group 2: Technological Advancements - Automation and robotics are key components of the modernization effort, improving speed, quality, and efficiency in the distribution process [5] - 98% of Cardinal Health's cold storage capacity has been upgraded to ensure precise handling of temperature-sensitive products [4] Group 3: Employee and Operational Benefits - The modernization strategy focuses on enhancing employee safety and ergonomics by allowing workers to interact with robotics outside of refrigerated zones [5] - Cardinal Health's business continuity plan is designed for flexibility and resilience, enabling rapid response during public health emergencies or unexpected disruptions [5]

Core Insights - Baxter International reported $2.84 billion in revenue for Q3 2025, a 5% year-over-year increase, but EPS decreased to $0.69 from $0.80 a year ago [1] - The revenue fell short of the Zacks Consensus Estimate of $2.87 billion, resulting in a surprise of -1.32%, while the EPS exceeded expectations by 15% [1] Financial Performance Metrics - U.S. Pharmaceuticals net sales were $177 million, slightly below the average estimate of $183.65 million, reflecting a -0.6% year-over-year change [4] - International Pharmaceuticals net sales reached $455 million, matching the average estimate and showing an 11% increase year-over-year [4] - Advanced Surgery net sales were $306 million, surpassing the average estimate of $289.33 million, with a year-over-year growth of 12.5% [4] - Other net sales skyrocketed to $101 million, significantly exceeding the estimated $91.79 million, marking a remarkable 494.1% increase year-over-year [4] - Infusion Therapies and Technologies net sales were $1.02 billion, below the estimated $1.08 billion, representing a -4.4% change compared to the previous year [4] Stock Performance - Baxter's shares have returned -4% over the past month, contrasting with the Zacks S&P 500 composite's +3.6% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]